Olaparib Methoxy Derivative
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

Olaparib Methoxy Derivative

● In Stock

Catalogue No.:VE0026034
CAS No.:N/A
Mol. Formula:C25H26N4O4
Mol. Weight:446.50 g/mol

Additional information on

Parent drug

Olaparib

IUPAC Name

4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-methoxybenzyl)phthalazin-1(2H)-one

Pharmacopeial Synonyms

N/A

Synonyms

N/A

Smiles

O=C(N1CCN(C(C2CC2)=O)CC1)C3=CC(CC4=NNC(C5=CC=CC=C54)=O)=CC=C3OC

InChI

InChI=1S/C25H26N4O4/c1-33-22-9-6-16(15-21-18-4-2-3-5-19(18)23(30)27-26-21)14-20(22)25(32)29-12-10-28(11-13-29)24(31)17-7-8-17/h2-6,9,14,17H,7-8,10-13,15H2,1H3,(H,27,30)

Description

Olaparib methoxy derivative impurity is a methoxylated analog arising from O-methylation of the parental olaparib scaffold during synthesis or storage. Typically characterized by a +14 Da mass shift in LC-MS and a distinct HPLC retention time, this impurity shows diagnostic 1H and 13C NMR signals for OCH3. Formation pathways include inadvertent methyl transfer from methylating reagents or solvent mediated methylation under acidic or oxidative conditions. Control strategy relies on optimized reaction quenching, chromatographic purification and targeted monitoring by LC-MS/HPLC with validated method limits. Identification, isolation and quantification support specification setting per ICH impurities guidance to mitigate impact on critical quality attributes and batch release.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url